Sana Biotechnology Inc. (NASDAQ: SANA) presented preclinical data for its SG293 therapy at the American Society of Gene & Cell ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE